** Inovio Pharmaceuticals' INO.O shares down 33% premarket to $1.43 after follow-on prices
** Plymouth Meeting, Pennsylvania-based firm announces ~14.3 mln shares along with warrants to buy additional 14.3 mln shares at $1.75 for $25 mln gross proceeds
** Offering price represents 18.2% discount to stock's last close
** It intends to use net proceeds primarily for development of clinical pipeline, preparing for a potential commercial launch of INO-3107, if approved, and for general purposes, per the prospectus
** INO-3107 is a potential treatment for recurrent respiratory papillomatosis, a benign tumor disease
** With ~36.7 mln shares outstanding, co has about $78 mln market cap through Weds
** INO shares on Weds ended up 4.9%, up 17% YTD
** Piper Sandler sole active bookrunner for the offering, joined by Oppenheimer
** Avg rating among 5 analysts is "buy" and median PT is $10, LSEG data reflects
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.